Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

STOCKWATCH: Suits in suites look to deal better hands in 2014

This article was originally published in Scrip

Executive Summary

As the great and the good of the healthcare world (as well as the rest of us) descend on San Francisco for the annual JP Morgan Healthcare conference from 13-16 January, the focus of attention may not be on the companies' formal presentations. In 2014, the most interesting meetings will be the ones you are not invited to, those that are held in the hotel suites within four or five blocks of Union Square.

You may also be interested in...



Stockwatch: Coronavirus And Commercialization

The prices of biotechnology and pharmaceutical sector indices continue to be comparatively robust in the face of big falls in global markets as investors expect new drugs and vaccines to be generated by the sector. While it is largely accepted that the life science sector will eventually ride to the rescue, bumper profits are far from guaranteed.

Stockwatch: Coronavirus And The Pharmaceutical Value Chain

Pharmaceutical shares are stronger than most as world stock markets dive downwards, but they are not immune to the coronavirus fallout. The effects will be felt by biopharma companies across many areas of their activity.

Stockwatch: Is Alnylam’s Rare Disease Business Model Sustainable?

Alnylam’s fourth-quarter and full-year 2019 earnings announcement was only one of eight announcements made by the company since early February. With the fundamental basis of its orphan drug business model still unvalidated by a profit, perhaps the more recent announcements are meant to distract investors’ attention with different metrics.

Topics

Related Companies

UsernamePublicRestriction

Register

SC023941

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel